ADCT Awaits Cami Trial Data, CSTL Boosts Revenue Outlook, ANNX To Report HD Trial Data In Q2

Castle Biosciences Inc. (CSTL) has increased its revenue outlook for 2022, based on the first-quarter results. The company now anticipates total revenue in 2022 in the range of $118 million to $123 million, up from its prior outlook of $115 million to $120 million. Revenue was $94.1 million in 2021.

from RTT - Top Story https://ift.tt/MrU720d
via IFTTT